You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Dyax climbs as analyst raises price target

istockphoto

Burlington-based Dyax Corp. got a higher price target from Needham & Co. analyst Serge Belanger, who reiterated a “buy” rating. The new price target is $13, up from $7.50, thanks to the experimental drug DX2930. “The DYAX story . . . now centers on DX2930, the company’s antibody under development for prophylactic HAE treatment,” Belanger said. He expects favorable study data soon. The drug is for hereditary angioedema, a rare acute inflammatory condition with severe swelling of the extremities, gastrointestinal tract, genitalia, and larynx.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com